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3Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UKBackground/Aims:To compare carotid intima-media thickness (IMT) – an index of early atherosclerosis – among
patients with non-alcoholic steatohepatitis (NASH), patients with chronic hepatitis B (HBV) or C (HCV) and control
subjects.
Methods:We studied 60 consecutive patients with biopsy-proven NASH, 60 patients with HCV, 35 patients with HBV,
and 60 healthy controls who were comparable for age and sex. Common carotid IMT was measured with ultrasonography
in all participants by a single operator blinded to subjects’ characteristics.
Results:Carotid IMT measurements were markedly diﬀerent among the groups; the lowest values were in controls, inter-
mediate in patients with HBV or HCV, and highest in those with NASH (0.84 ± 0.1 vs. 0.97 ± 0.1 vs. 1.09 ± 0.2 vs.
1.23 ± 0.2 mm, respectively; p < 0.001). The marked diﬀerences in carotid IMT that were observed among the groups were
little aﬀected by adjustment for age, sex, body mass index, smoking, LDL cholesterol, insulin resistance (by homeostasis
model assessment) and components of the Adult Treatment Panel III-deﬁned metabolic syndrome. Concordantly, in logis-
tic regression analysis, NASH, HBV and HCV predicted carotid IMT independent of potential confounders.
Conclusions:These data suggest that NASH, HCV and HBV are strongly associated with early atherosclerosis indepen-
dent of classical risk factors, insulin resistance and metabolic syndrome components.
 2007 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Keywords: Non-alcoholic fatty liver disease; Chronic viral hepatitis; Atherosclerosis; Metabolic syndrome; Insulin
resistance1. Introduction
Non-alcoholic fatty liver disease (NAFLD) aﬀects a
substantial proportion of the general population and is
commonly associated with many features of the meta-
bolic syndrome (MetS) [1–4]. The importance of0168-8278/$32.00  2007 European Association for the Study of the Liver.
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E-mail address: targher@sacrocuore.it (G. Targher).NAFLD and its relationship to the MetS is now increas-
ingly recognized, and this has stimulated an interest in
the possible role of NAFLD in the development and
progression of cardiovascular disease (CVD). Recent
data suggest that NAFLD may also be linked to
increased CVD prevalence and incidence [5–13],
although this needs verifying in larger studies.
Currently, very few data are available on relation-
ships between CVD and chronic hepatitis B (HBV)
and C (HCV). Although the relationship between
HBV and CVD remains controversial [14,15], a large
cohort study recently found an increased prevalence of
carotid atherosclerosis in HBV carriers [16]. Similarly,Published by Elsevier B.V. All rights reserved.
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associated with higher frequency of carotid atheroscle-
rosis [17]. On the other hand, there are still controversial
results as to whether HCV antibody seropositivity alone
– regardless of HCV-RNA positivity – is associated with
higher CVD risk [18–23].
To our knowledge, no studies have previously com-
pared carotid intima-media thickness (IMT), a reliable
index of early atherosclerosis [24], among patients with
NAFLD and those with chronic HBV or HCV.
Clariﬁcation of this aspect may help to explain the
underlying mechanisms, and may be of clinical impor-
tance in planning preventative and therapeutic strate-
gies. Indeed, the impact of NAFLD and chronic viral
hepatitis on CVD risk deserves particular attention in
view of the implications for screening/surveillance strat-
egies in the growing number of patients.
The purpose of this study was to assess carotid IMT
in patients with NASH, and to compare them with those
of patients with HBV or HCV, and control subjects.2. Patients and methods
Sixty consecutive patients with diagnosis of NASH, 60 patients
with diagnosis of chronic HCV infection and 35 patients with diagnosis
of chronic HBV infection were recruited from our clinic. Sixty healthy
volunteers were recruited from hospital staﬀ members and relatives.
The four groups of participants were selected for matching for age
and sex. All patients had chronically elevated liver enzymes and most
of them had hepatic steatosis on ultrasound. Control subjects had nor-
mal liver tests and negative ultrasonography. Most NASH patients
have been included in a study assessing the association between carotid
IMT and liver histopathology [9].
NASH diagnosis was based on liver biopsy and exclusion of other
causes of chronic liver disease (alcohol intake >20 g/day, viral hepati-
tis, autoimmune hepatitis or medications). HCV diagnosis was based
on seropositivity of anti-HCV and HCV-RNA and exclusion of other
causes of chronic liver disease. HBV diagnosis was based on seropos-
itivity of HBV antigens and antibodies and exclusion of other causes of
chronic liver disease; all of our HBV-infected patients had seropositiv-
ity of HBsAg, anti-HBc and anti-HBe but seronegativity of HBeAg.
None of participants had any clinical evidence of cirrhosis, overt
nephropathy, diabetes or CVD. Among HCV-infected patients, only
eight of them had been treated previously for HCV (non-responders
to therapy), but therapy was completed at least 6 months prior to study
enrolment. The local Ethics Committee approved the study. All partic-
ipants provided written informed consent.
Venous blood was drawn in the morning after an overnight fast.
Plasma liver tests and other biochemical blood measurements were
determined by standard laboratory procedures. Reference ranges
for serum aminotransferase concentrations were 10–35 U/L for
women and 10–50 U/L for men, respectively. Serum insulin was
measured with a radio-immunoassay method. Hepatitis C virus
serology was determined by qualitative detection of HCV antibody
using an enzyme-linked immunosorbent assay (The Vitros anti-
HCV assay, Ortho-Clinical Diagnostics, Amersham, UK), and
HCV-RNA levels and its major genotypes using reverse-transcrip-
tion polymerase chain reaction (Amplicor HCV test, v2.0, Roche
Diagnostics, Milan, Italy). Hepatitis B virus serology was deter-
mined by qualitative detection of HBV antigens and antibodies
using enzyme-linked immunosorbent assays (Ortho-Clinical Diag-
nostics). Low-density lipoprotein (LDL) cholesterol was calculated
by the Friedewald’s formula. An oral glucose-tolerance test was per-
formed in all participants; four NASH patients had impaired glu-
cose tolerance (2-h glucose >7.8 and <11.1 mmol/L), whereas theremaining participants had normal glucose tolerance. Insulin resis-
tance was calculated by the homeostasis model assessment
(HOMA-IR score) [25].
Body mass index (BMI) was calculated by dividing weight in kilo-
grams by height in meters squared. Waist circumference was measured
at the level of the umbilicus. Blood pressure was measured in triplicate
with a standard mercury manometer. Information on alcohol con-
sumption and smoking history was obtained from all participants by
a questionnaire [9].
Metabolic syndrome was diagnosed by the Adult Treatment Panel
(ATP)-III deﬁnition [26]. In accordance with this deﬁnition, a person
was classiﬁed as having the syndrome if he/she had at least three of
the following ﬁve components: (1) waist circumference >102 cm in
males or >88 cm in females, (2) fasting glucose P6.1 mmol/L or on
treatment, (3) triglycerides P1.70 mmol/L, (4) HDL <1.0 mmol/L in
males and <1.29 mmol/L in females, or on treatment, and (5) blood
pressure P130/85 mmHg or on treatment. Only eight patients were
treated with statins or ramipril.
A single operator blinded to subjects’ characteristics measured com-
mon carotid IMT using ultrasonography. IMT measurements were
made bilaterally in the 1-cm segment proximal to the dilatation of the
carotid bulb, as previously described [5,7,9]. All ultrasonic examina-
tions were stored on a super VHS video system for subsequent oﬄine
processing. Video images were captured in end-diastole of the cardiac
cycle by triggering the electrocardiogram. The frozen video images were
digitized and transferred for further analysis to a personal computer.
IMT measurements were made by edge-detection techniques (and not
by electronic calipers) by a single operator blinded to patients’ details.
For each subject, three maximum values of carotid IMT on both sides
were measured, on the anterior, lateral and posterior projection of the
near and far wall. All readings were then averaged. Repeated measure-
ments on the same subjects gave coeﬃcients of variation below 9% [9].
A carotid plaque was deﬁned as a focal thickening ofP1.2 mm at the
level of common carotid artery [6,9,24]. No participants had clinically
relevant carotid stenosis (>60%).
Liver biopsy specimens were available only in NASH patients. An
experienced hepato-pathologist blinded to subjects’ details scored liver
biopsy specimens using the classiﬁcation of Brunt [27]. NASH was
deﬁned as the presence of steatosis plus lobular inﬂammation plus hepa-
tocellular ballooning or steatosis plus any stage of ﬁbrosis. Liver histol-
ogy results inNASHpatients showedNASHwith ﬁbrosis stage of 0 in 21
subjects, NASH/ﬁbrosis stage 1 in 23 subjects, NASH/ﬁbrosis stage 2 in
11 subjects, andNASH/ﬁbrosis stage 3 in 5 subjects; none had cirrhosis.
2.1. Statistical analysis
Data are means ± SD or proportions. Skewed variables (triglycer-
ides, liver enzymes and HOMA-IR score) were logarithmically trans-
formed to improve normality prior to analysis. Statistical analyses
included one-way analysis of variance and chi-squared test (for categor-
ical variables). Analysis of covariance was used to assess the signiﬁcance
of diﬀerences in carotid IMT among the groups after adjustment for
potential confounders (sex, age, BMI, smoking, LDL cholesterol,
HOMA-IR score and MetS components). After pooling subjects, the
independence of associations of variables with carotid IMT was also
assessed by multivariate linear (when the dependent variable, i.e., carot-
id IMT, was entered as a continuous variable) or logistic (when carotid
IMT was modelled as categorical variable and subjects were stratiﬁed
into those belonging to the top quartile vs. those belonging to the other
three quartiles) regression analyses. In the fully adjusted regression
models, together with the presence of NASH, HBV and HCV (included
as categorical variables), sex, age, BMI, smoking, LDL cholesterol,
HOMA-IR score and the individual components of the MetS (consid-
ered as continuous or categorical measures) were also included as covar-
iates. p-values <0.05 were considered statistically signiﬁcant.3. Results
The baseline characteristics of the study participants
are given in Table 1. Because of the study design, the
Fig. 1. Mean (±SD) values of carotid artery IMT and prevalence of
carotid atherosclerotic plaques in controls (white bars, n = 60), HBV-
infected patients (lined bars, n = 30), HCV-infected patients (grey bars,
n = 60) and NASH patients (black bars, n = 60). All data are adjusted
for age, sex, body mass index, cigarette smoking, LDL-cholesterol,
HOMA-estimated insulin resistance and the individual components of the
ATP III-deﬁned metabolic syndrome.
Table 1
Baseline characteristics of the study participants
NASH patients HCV patients HBV patients Control subjects
n 60 60 35 60
Sex (M/F) 34/16 34/16 23/12 34/16
Age (years) 46 ± 3 46 ± 3 47 ± 3 46 ± 3
BMI (kg/m2) 28 ± 3a,b 26 ± 3a 24 ± 2 25 ± 2
Waist circumference (cm) 97 ± 6a 93 ± 5a 85 ± 3 86 ± 4
Systolic blood pressure (mmHg) 127 ± 7a,b 121 ± 5 120 ± 4 123 ± 4
Diastolic blood pressure (mmHg) 81 ± 6 76 ± 4 77 ± 4 78 ± 4
Current smokers (%) 26.7% 25.0% 31.4% 33.3%
Fasting glucose (mmol/L) 5.6 ± 0.7 5.4 ± 0.6 5.3 ± 0.3 5.2 ± 0.3
Two-hour glucose (mmol/L) 6.9 ± 1.2 6.1 ± 1.0 6.0 ± 1.1 5.8 ± 1.1
Fasting insulin (mU/L) 15.0 ± 4a,b 11.6 ± 4a 5.9 ± 2 6.1 ± 2
HOMA-insulin resistance score 3.93 ± 2.1a,b 2.91 ± 2.0a 1.42 ± 1.9 1.45 ± 1.8
Triglycerides (mmol/L) 1.52 ± 1.0a,b 1.17 ± 0.7a 0.82 ± 0.4 0.90 ± 0.5
HDL cholesterol (mmol/L) 1.37 ± 0.6a 1.46 ± 0.4 1.50 ± 0.5 1.51 ± 0.5
LDL cholesterol (mmol/L) 3.10 ± 0.5 2.80 ± 0.7 2.89 ± 0.3 3.04 ± 0.3
AST (U/L) 46 ± 51a 58 ± 44a 52 ± 41a 18 ± 4
ALT (U/L) 106 ± 70a 115 ± 83a 102 ± 76a 20 ± 5
GGT (U/L) 49 ± 36a 41 ± 30a 47 ± 27a 17 ± 4
ATP III -metabolic syndrome (%) 52.5%a,b 25%a 0% 0%
Carotid IMT (mm) 1.23 ± 0.2a,b 1.09 ± 0.2a 0.97 ± 0.1c 0.84 ± 0.1
Carotid plaques (%) 70.0%a,b 37.5%a 30.0%c 15.0%
Data are means ± SD unless otherwise indicated.
a p < 0.001 vs. control subjects.
b p < 0.05 or less vs. patients with HCV or HBV.
c p < 0.05 vs. control subjects.
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sex. Compared with controls, HBV-infected patients
did not signiﬁcantly diﬀer in any of the study variables,
except for liver enzymes. MetS and its individual
components occurred more frequently in patients with
NASH or HCV compared with HBV-infected patients
and control subjects. Accordingly, NASH and HCV
patients also had higher values of insulin and HOMA-
IR score – that were remarkably higher in the former
– than those in HBV-infected patients and control
subjects. Smoking status, plasma LDL cholesterol
and glucose concentrations did not diﬀer among the
groups.
Among HCV patients, forty-three (71.7%) patients
were infected with HCV genotype 1, 15 (25%) with geno-
type 2 and remaining 2 (3.3%) patients with genotype 3.
Carotid IMT measurements were remarkably diﬀer-
ent among the study participants (Table 1). The lowest
values were in controls, the intermediate in patients with
HBV or HCV, and the highest levels in those with
NASH. Patients with NASH or chronic viral hepatitis
also had greater prevalence of carotid plaques (focal
thickening P1.2 mm at the level of carotid artery) than
controls. No diﬀerences in carotid IMTs were found in
HCV-infected patients after stratiﬁcation according to
HCV genotype distribution (not shown).
As shown in Fig. 1, the diﬀerences in carotid IMT
and plaques that were observed among the groups
were little aﬀected by adjustment for age, sex, BMI,smoking, LDL cholesterol, insulin resistance and
MetS components (included as continuous measures).
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(n = 8) on statins or anti-hypertensive drugs have been
excluded.
In univariate logistic regression analysis, together
with NASH (OR 2.41, 95% CI 1.6–3.9; p < 0.001),
HCV (OR 1.97, 95% CI 1.3–3.1; p < 0.001) and HBV
(OR 1.45, 95% CI 1.1–1.9; p < 0.05), older age, male
sex, BMI, waist circumference, blood pressure, smoking,
HOMA-IR score and LDL cholesterol were signiﬁcantly
associated with carotid IMT. In the fully adjusted
regression model, older age (OR 1.14, 95% CI 1.06–
1.18; p < 0.001), raised blood pressure values (OR
2.01, 95% CI 1.5–2.7; p < 0.001), HOMA-IR score
(OR 1.73, 95% CI 1.2–2.3; p < 0.001), and presence of
NASH (OR 1.96, 95% CI 1.3–2.9; p < 0.001), HCV
(OR 1.61, 95% CI 1.1–2.5; p < 0.001) or HBV (OR
1.40, 95% CI 1.1–1.7; p < 0.05) predicted carotid IMT
(4th quartile vs. quartiles 1st–3rd) independent of other
potential confounding factors (sex, smoking, BMI, waist
circumference, LDL cholesterol and triglycerides).
Almost identical results were found in models in which
the MetS components were entered as categorical
measures (not shown).
Similar results were found when we considered carot-
id IMT as a continuous measure and performed multi-
variate linear regression analyses. Also in this case,
NASH (multiple-adjusted r-value = 0.63; p < 0.001),
HCV (r-value = 0.44; p < 0.001) and HBV (r-val-
ue = 0.32; p < 0.05) were signiﬁcantly associated with
carotid IMT after adjusting for the above-reported
covariates.4. Discussion
The main ﬁndings of this study are as follows: (1)
compared with controls, patients with NASH and those
with HCV or HBV have increased carotid IMT and pla-
ques, as early signs of atherosclerosis, (2) carotid IMT
and plaques are higher for individuals with NASH than
for those with HCV or HBV, and (3) the diﬀerences in
early carotid atherosclerosis that are observed among
the groups remained signiﬁcant after adjustment for a
broad spectrum of CVD risk factors, including insulin
resistance and components of the MetS, a chronic
inﬂammatory cardiovascular condition that is closely
related to NASH and HCV [1–4,28].
As regards NASH, our ﬁndings complement recent
observations that NAFLD is independently associated
with greater carotid IMT and plaques [5–9], and lower
endothelial ﬂow-mediated vasodilation [29], and that
NAFLD is associated with higher all-cause death,
and predicts the risk of future CVD events [11–13].
The possible biological mechanisms linking NAFLD
and CVD have been extensively reviewed elsewhere
[30].As regards HCV and HBV infections, few data are
available on relationships between chronic viral hepati-
tis and CVD. In particular, our results extend those of
the only one previously published study demonstrating
that chronic HCV infection was associated with higher
frequency of carotid atherosclerotic plaques indepen-
dent of other prognostic factors [17]. On the contrary,
there is uncertainty whether HCV antibody seropositiv-
ity alone is associated with higher CVD risk [18–23].
Similarly, although the data on relationships between
HBV and CVD are still controversial [14–16,20], a
recent cross-sectional study from a health-screening test
cohort found a strong association between HBV carrier
status and carotid atherosclerosis [16].
A signiﬁcant strength of this study was that carotid
IMT was measured in a large sample of consecutive
patients with biopsy-proven NASH and, for compari-
son, in samples of HCV- and HBV-infected patients
who were comparable for age and sex (i.e., the strongest
CVD risk factors). Notably, our patients were free of
diagnosed CVD, diabetes and cirrhosis, and had a
well-preserved liver function; the evaluation of patients
with such complications would have probably con-
founded the interpretation of the data.
The key ﬁnding of this study was that carotid IMT
and plaques were greater for patients with NASH than
for those with HBV or HCV (or controls). This ﬁnding
partly supports the results of Sanyal [31], who compared
the outcomes of cirrhotic patients with NASH or HCV.
They found that compensated cirrhosis due to NASH is
associated with a lower total mortality compared with
that due to HCV, but that CVD mortality is greater in
those with NASH. Moreover, this ﬁnding supports
recent data suggesting an increased CVD incidence
among cardiac or renal transplant recipients infected
with HCV or HBV [32–34].
Clearly, we must be cautious in making any causal
inference, given the cross-sectional design of the study.
The biological mechanisms by which NASH, HBV
and HCV might contribute to CVD are poorly under-
stood. In particular, the most likely explanation for
our ﬁndings could be that pre-clinical carotid atheroscle-
rosis in NASH and HCV – but probably not in HBV
which is a chronic liver disease not speciﬁcally associat-
ed with the MetS components – mainly reﬂects the pres-
ence of underlying metabolic abnormalities, principally
visceral obesity and insulin resistance. However, NASH
and HCV might also act as a stimulus for further
increased whole-body insulin resistance and dyslipida-
emia, leading to accelerated atherosclerosis. This
hypothesis is partly supported by prospective studies
demonstrating that NASH and HCV predict new-onset
type 2 diabetes independent of obesity [35–39].
However, because in our study NASH, HBV and
HCV were associated with carotid atherosclerosis inde-
pendent of classical risk factors, insulin resistance and
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additional atherogenic mechanisms are involved, thus
raising the possibility that liver may be not simply a
marker of CVD but may also be involved in its patho-
genesis [30].
A common, underlying, mechanism linking NASH,
HCV, HBV and CVD might be represented by increased
hepatic oxidative stress and chronic inﬂammation,
which have been shown to be associated with CVD
pathogenesis [40,41], and are thought to be key factors
in the progression of these liver diseases [2,28,42].
Although this is still a controversial issue, similar to
other infectious agents (cytomegalovirus, Helicobacter
pylori and Chlamydia pneumoniae) possibly implicated
in CVD pathogenesis [43], persistent HCV or HBV
infections could induce hepatic/systemic chronic inﬂam-
mation and thus might contribute to CVD pathogenesis.
Consistent with the hypothesis that liver inﬂammation
plays a role in CVD pathogenesis, we consider that the
higher frequency of carotid plaques in NASH patients
compared to HCV and HBV patients – which appears
to be also independent of the higher MetS components
in NASH – might be explained by a higher underlying
liver inﬂammation in NASH. Indeed, we have previous-
ly found a strong, graded, relationship between the
severity of NAFLD histology and carotid IMT and pla-
ques in these patients [9]. However, the lack of liver
biopsy specimens in our HCV- and HBV-infected
patients does not allow us to deﬁnitively answer this
question.
Decreased concentrations of adiponectin, an adipose-
secreted protein with anti-inﬂammatory and anti-athero-
genic properties [44], might represent another common,
underlying, mechanism linking NASH, HCV and CVD.
It has been demonstrated that hypoadiponectinemia
correlateswith the severity ofNAFLDhistology indepen-
dent of insulin resistance and other MetS components
[45–47]. Similar results were found in some, but not all,
studies assessing plasma adiponectin concentrations
among HCV-infected patients [48–51].
Interestingly, O’Leary reported that a carotid IMT
value 60.86 mm carries a low risk of developing CVD,
whereas an IMT value P1.10 carries a high risk of
developing CVD [52]. It is worth emphasizing that the
mean IMT values we found among controls, HBV,
HCV and NASH patients were 0.84, 0.97, 1.09 and
1.23 mm, respectively. Thus, our ﬁndings might have
important clinical implications. These data strongly
emphasize the clinical importance of evaluating the
global CVD risk in patients diagnosed with NASH or
HBV or HCV; patients having increased carotid IMT
could be candidates not only for aggressive treatment
of their liver disease, but also for aggressive treatment
of underlying CVD risk factors; this would help to mod-
ify and potentially decrease the global CVD risk of these
patients.This study has some limitations that should be noted.
The cross-sectional design of our study precludes the
establishment of causal or temporal relations among
chronic liver diseases, carotid atherosclerosis and MetS.
Prospective studies will be required to sort out the time
sequence of events. Although our results have been
adjusted for HOMA-IR score, a reliable method for esti-
mating insulin resistance [25], we did not directly mea-
sure insulin sensitivity (by euglycemic clamp) in our
population, so we cannot be certain that identical results
could be obtained after adjustment for the clamp-mea-
sured insulin resistance (especially among patients with
NASH or HCV who are hyperinsulinaemic and insulin
resistant compared with controls). Another possible lim-
itation of this study is that in the control subjects, the
exclusion of NAFLD was based on medical history,
blood testing, and ultrasound imaging, but was not con-
ﬁrmed by liver biopsy. However, although some non-
diﬀerential misclassiﬁcation of NAFLD on the basis of
ultrasound is likely (i.e., some of the controls could have
underlying NAFLD, despite normal liver enzymes and a
negative ultrasound), this limitation would serve to
attenuate the magnitude of our eﬀect measures toward
the null; thus, our results can probably be considered
as conservative estimates of the relationship between
NAFLD and carotid IMT.
In conclusion, our ﬁndings suggest that NASH,
HCV and HBV (in patients without cirrhosis and
with a well-preserved liver function) are associated
with early signs of atherosclerosis, independent of
classical risk factors, insulin resistance and compo-
nents of the metabolic syndrome. Larger studies are
needed to conﬁrm these ﬁndings and to elucidate
the underlying biologic mechanisms before causality
can be ﬁrmly established.
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